Highlighting the sector’s progress, Commerce Secretary Rajesh Agrawal said that India continues to maintain its leadership in generic medicines while steadily advancing towards innovation-driven growth. The transformation reflects the industry’s increasing focus on research, development, quality standards and the production of advanced pharmaceutical products for international markets.
Agrawal outlined the government’s ambitious objective of achieving USD 50 billion in pharmaceutical exports by 2030. He stated that this target will be pursued through a strategic emphasis on quality enhancement, innovation, regulatory excellence and diversification of export markets.
According to the Commerce Secretary, India’s pharmaceutical industry currently comprises more than 10,500 manufacturing units and over 60,000 generic brands spanning 60 therapeutic categories. The extensive manufacturing network and broad product portfolio have enabled the country to strengthen its global presence and meet growing healthcare demands across multiple regions.
Agrawal further noted that more than 60 per cent of India’s pharmaceutical exports are directed towards highly regulated markets. This achievement reflects increasing international confidence in the country’s pharmaceutical manufacturing capabilities, regulatory compliance and quality standards.
The continued expansion of pharmaceutical exports underscores India’s growing influence in the global healthcare sector. With a strong manufacturing base, leadership in generic medicines and a renewed focus on innovation, the industry is positioned to play a critical role in advancing the country’s export ambitions and strengthening its standing in international pharmaceutical markets.
About The Author
Comment List